HIV-associated lipodystrophy: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Infobox medical condition | |||
| name = HIV-associated lipodystrophy | |||
| synonyms = HALS | |||
| field = [[Endocrinology]], [[Infectious disease]] | |||
| symptoms = [[Fat redistribution]], [[Insulin resistance]], [[Dyslipidemia]] | |||
| complications = [[Cardiovascular disease]], [[Diabetes mellitus]] | |||
| onset = Typically after starting [[antiretroviral therapy]] | |||
| duration = Chronic | |||
| causes = [[Antiretroviral therapy]] | |||
| risks = Use of [[protease inhibitors]], [[nucleoside reverse transcriptase inhibitors]] | |||
| diagnosis = Clinical evaluation, [[Body composition analysis]] | |||
| differential = [[Cushing's syndrome]], [[Metabolic syndrome]] | |||
| prevention = Careful selection of antiretroviral regimen | |||
| treatment = [[Lifestyle modification]], [[Switching antiretroviral drugs]], [[Metformin]], [[Growth hormone]] | |||
| prognosis = Variable, depends on management | |||
| frequency = Common among individuals on long-term antiretroviral therapy | |||
}} | |||
'''HIV-associated lipodystrophy''' ('''HALS''') is a condition that affects individuals who are [[HIV|HIV-positive]], and is characterized by a redistribution of [[body fat|fat]] in the body. This condition is often associated with [[antiretroviral therapy]] (ART), which is used to manage HIV infection. | '''HIV-associated lipodystrophy''' ('''HALS''') is a condition that affects individuals who are [[HIV|HIV-positive]], and is characterized by a redistribution of [[body fat|fat]] in the body. This condition is often associated with [[antiretroviral therapy]] (ART), which is used to manage HIV infection. | ||
== Symptoms == | == Symptoms == | ||
The symptoms of HIV-associated lipodystrophy can vary widely among individuals. Some people may experience significant changes in their physical appearance, including: | The symptoms of HIV-associated lipodystrophy can vary widely among individuals. Some people may experience significant changes in their physical appearance, including: | ||
* [[Lipoatrophy]]: This involves the loss of subcutaneous fat, particularly in the face, arms, and legs. | * [[Lipoatrophy]]: This involves the loss of subcutaneous fat, particularly in the face, arms, and legs. | ||
* [[Lipohypertrophy]]: This involves the accumulation of fat in areas such as the abdomen, breasts, and back of the neck. | * [[Lipohypertrophy]]: This involves the accumulation of fat in areas such as the abdomen, breasts, and back of the neck. | ||
Other symptoms can include [[insulin resistance]], [[dyslipidemia]], and an increased risk of [[cardiovascular disease]]. | Other symptoms can include [[insulin resistance]], [[dyslipidemia]], and an increased risk of [[cardiovascular disease]]. | ||
== Causes == | == Causes == | ||
The exact cause of HIV-associated lipodystrophy is not fully understood. However, it is believed to be related to the use of certain antiretroviral drugs, particularly those in the class of [[protease inhibitors]] and [[nucleoside reverse transcriptase inhibitors]] (NRTIs). Other factors, such as the duration of HIV infection and the individual's genetic makeup, may also play a role. | The exact cause of HIV-associated lipodystrophy is not fully understood. However, it is believed to be related to the use of certain antiretroviral drugs, particularly those in the class of [[protease inhibitors]] and [[nucleoside reverse transcriptase inhibitors]] (NRTIs). Other factors, such as the duration of HIV infection and the individual's genetic makeup, may also play a role. | ||
== Treatment == | == Treatment == | ||
Treatment for HIV-associated lipodystrophy can involve a combination of lifestyle changes, medication adjustments, and sometimes surgery. Lifestyle changes can include diet and exercise to manage weight and improve insulin sensitivity. In some cases, switching to a different antiretroviral drug can help to alleviate symptoms. Surgical options, such as liposuction or fat grafting, may be considered for individuals with severe lipoatrophy or lipohypertrophy. | Treatment for HIV-associated lipodystrophy can involve a combination of lifestyle changes, medication adjustments, and sometimes surgery. Lifestyle changes can include diet and exercise to manage weight and improve insulin sensitivity. In some cases, switching to a different antiretroviral drug can help to alleviate symptoms. Surgical options, such as liposuction or fat grafting, may be considered for individuals with severe lipoatrophy or lipohypertrophy. | ||
== See also == | == See also == | ||
* [[HIV/AIDS]] | * [[HIV/AIDS]] | ||
* [[Antiretroviral therapy]] | * [[Antiretroviral therapy]] | ||
| Line 25: | Line 33: | ||
* [[Lipoatrophy]] | * [[Lipoatrophy]] | ||
* [[Lipohypertrophy]] | * [[Lipohypertrophy]] | ||
== References == | == References == | ||
<references /> | <references /> | ||
{{stub}} | {{stub}} | ||
[[Category:HIV]] | [[Category:HIV]] | ||
[[Category:Lipodystrophy]] | [[Category:Lipodystrophy]] | ||
[[Category:Medical conditions]] | [[Category:Medical conditions]] | ||
[[Category:Endocrine, nutritional and metabolic diseases]] | [[Category:Endocrine, nutritional and metabolic diseases]] | ||
Latest revision as of 05:48, 4 April 2025
| HIV-associated lipodystrophy | |
|---|---|
| Synonyms | HALS |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Fat redistribution, Insulin resistance, Dyslipidemia |
| Complications | Cardiovascular disease, Diabetes mellitus |
| Onset | Typically after starting antiretroviral therapy |
| Duration | Chronic |
| Types | N/A |
| Causes | Antiretroviral therapy |
| Risks | Use of protease inhibitors, nucleoside reverse transcriptase inhibitors |
| Diagnosis | Clinical evaluation, Body composition analysis |
| Differential diagnosis | Cushing's syndrome, Metabolic syndrome |
| Prevention | Careful selection of antiretroviral regimen |
| Treatment | Lifestyle modification, Switching antiretroviral drugs, Metformin, Growth hormone |
| Medication | N/A |
| Prognosis | Variable, depends on management |
| Frequency | Common among individuals on long-term antiretroviral therapy |
| Deaths | N/A |
HIV-associated lipodystrophy (HALS) is a condition that affects individuals who are HIV-positive, and is characterized by a redistribution of fat in the body. This condition is often associated with antiretroviral therapy (ART), which is used to manage HIV infection.
Symptoms[edit]
The symptoms of HIV-associated lipodystrophy can vary widely among individuals. Some people may experience significant changes in their physical appearance, including:
- Lipoatrophy: This involves the loss of subcutaneous fat, particularly in the face, arms, and legs.
- Lipohypertrophy: This involves the accumulation of fat in areas such as the abdomen, breasts, and back of the neck.
Other symptoms can include insulin resistance, dyslipidemia, and an increased risk of cardiovascular disease.
Causes[edit]
The exact cause of HIV-associated lipodystrophy is not fully understood. However, it is believed to be related to the use of certain antiretroviral drugs, particularly those in the class of protease inhibitors and nucleoside reverse transcriptase inhibitors (NRTIs). Other factors, such as the duration of HIV infection and the individual's genetic makeup, may also play a role.
Treatment[edit]
Treatment for HIV-associated lipodystrophy can involve a combination of lifestyle changes, medication adjustments, and sometimes surgery. Lifestyle changes can include diet and exercise to manage weight and improve insulin sensitivity. In some cases, switching to a different antiretroviral drug can help to alleviate symptoms. Surgical options, such as liposuction or fat grafting, may be considered for individuals with severe lipoatrophy or lipohypertrophy.
See also[edit]
References[edit]
<references />
